SenzaGen Financials
| SENZA Stock | SEK 6.95 0.10 1.42% |
SenzaGen |
Please note, the imprecision that can be found in SenzaGen's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of SenzaGen AB. Check SenzaGen's Beneish M Score to see the likelihood of SenzaGen's management manipulating its earnings.
SenzaGen Stock Summary
SenzaGen competes with Immunovia Publ, Sedana Medical, KABE Group, IAR Systems, and Mekonomen. SenzaGen AB, together with its subsidiary, markets, sells, and performs in vitro genomic allergen rapid detection sensitization tests for the screening of pharmaceutical candidates, and safety assessment of chemicals and cosmetic ingredients in Sweden and internationally. SenzaGen AB was incorporated in 2010 and is headquartered in Lund, Sweden. SenzaGen is traded on Stockholm Stock Exchange in Sweden.| Instrument | Sweden Stock View All |
| Exchange | Stockholm Exchange |
| ISIN | SE0010219626 |
| Business Address | Building 401, Lund, |
| Sector | Healthcare |
| Industry | Biotechnology |
| Benchmark | Dow Jones Industrial |
| Website | senzagen.com |
| Phone | 46 4 62 75 60 00 |
| Currency | SEK - Swedish Kronor |
You should never invest in SenzaGen without having analyzed its financial statements. Do not rely on someone else's analysis or guesses about the future performance of SenzaGen Stock, because this is throwing your money away. Analyzing the key information contained in SenzaGen's financial statements can give you an edge over other investors and help to ensure that your investments perform well for you.
SenzaGen Key Financial Ratios
There are many critical financial ratios that SenzaGen's investors are exposed to on a daily basis, but they are usually grouped into few meaningful categories from each financial statement that SenzaGen AB reports annually and quarterly.SenzaGen Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining SenzaGen's current stock value. Our valuation model uses many indicators to compare SenzaGen value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across SenzaGen competition to find correlations between indicators driving SenzaGen's intrinsic value. More Info.SenzaGen AB is currently regarded as top stock in return on equity category among its peers. It also is currently regarded as top stock in return on asset category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the SenzaGen's earnings, one of the primary drivers of an investment's value.SenzaGen AB Systematic Risk
SenzaGen's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. SenzaGen volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was thirty-six with a total number of output elements of twenty-five. The Beta measures systematic risk based on how returns on SenzaGen AB correlated with the market. If Beta is less than 0 SenzaGen generally moves in the opposite direction as compared to the market. If SenzaGen Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one SenzaGen AB is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of SenzaGen is generally in the same direction as the market. If Beta > 1 SenzaGen moves generally in the same direction as, but more than the movement of the benchmark.
SenzaGen December 2, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of SenzaGen help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of SenzaGen AB. We use our internally-developed statistical techniques to arrive at the intrinsic value of SenzaGen AB based on widely used predictive technical indicators. In general, we focus on analyzing SenzaGen Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build SenzaGen's daily price indicators and compare them against related drivers.
| Information Ratio | (0.11) | |||
| Maximum Drawdown | 11.26 | |||
| Value At Risk | (4.11) | |||
| Potential Upside | 4.08 |
Additional Tools for SenzaGen Stock Analysis
When running SenzaGen's price analysis, check to measure SenzaGen's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy SenzaGen is operating at the current time. Most of SenzaGen's value examination focuses on studying past and present price action to predict the probability of SenzaGen's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move SenzaGen's price. Additionally, you may evaluate how the addition of SenzaGen to your portfolios can decrease your overall portfolio volatility.